Nanjing Bioheng Biotech Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2017-03-27
- Employees
- 101
- Market Cap
- -
- Website
- https://www.bioheng.com
Clinical Trials
5
Active:1
Completed:0
Trial Phases
2 Phases
Early Phase 1:4
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Early Phase 1
4 (80.0%)Not Applicable
1 (20.0%)A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM
Not Applicable
Active, not recruiting
- Conditions
- Type 1 Diabetes
- Interventions
- Drug: RD13-02 cell infusion
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT07142161
- Locations
- 🇨🇳
Bioheng, Nanjing, China
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
Early Phase 1
Recruiting
- Conditions
- SLESystemic SclerosisIIMNMOSDMSMGANCA Associated Vasculitis (AAV)
- Interventions
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06775912
- Locations
- 🇨🇳
The First People's Hospital of Lianyungang, Lianyungang, Jiangus, China
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
Early Phase 1
Recruiting
- Conditions
- Systemic Lupus ErythematosusSystemic SclerosisANCA Associated VasculitisIdiopathic Inflammatory MyopathiesAutoimmune DiseasesSjogren's Syndrome
- Interventions
- Drug: RD06-04 CART Cell Injection
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06549296
- Locations
- 🇨🇳
Xuzhou Medical University Affiliated Hospital, Xuzhou, Jiangsu, China
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Early Phase 1
Not yet recruiting
- Conditions
- SclerosisSLE (Systemic Lupus)ANCA Associated VasculitisIIMSSNMO Spectrum DisorderMSMG
- Interventions
- Drug: RD06-04 cell infusion
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06548620
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
Early Phase 1
Recruiting
- Conditions
- SLE (Systemic Lupus)Sjogren's SyndromeANCA Associated VasculitisIdiopathic Inflammatory MyopathiesSystemic SclerosisAutoimmune Diseases
- Interventions
- Drug: RD06-04 or RD06-05 CART Cell Injection
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06548607
- Locations
- 🇨🇳
The Third the People's Hospital of Bengbu, Bengbu, Anhui, China
News
No news found